Scholar Rock Holding (Nasdaq:SRRK) - 주가, 뉴스 및 분석

SRRK 주식 개요

바이오 제약 회사인 스콜라 락 홀딩 코퍼레이션은 단백질 성장 인자에 의한 신호 전달이 근본적인 역할을 하는 중증 질환 치료를 위한 의약품의 발견, 개발 및 전달에 중점을 두고 있습니다.

SRRK 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

Trading at 64.4% below our estimate of its fair value

Revenue is forecast to grow 64.67% per year

위험 분석

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Scholar Rock Holding Corporation 경쟁사

Keros Therapeutics

NasdaqGM:KROS

US$2.2b

Inhibrx

NasdaqGM:INBX

US$1.8b

Syndax Pharmaceuticals

NasdaqGS:SNDX

US$1.6b

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Scholar Rock Holding
과거 주가
현재 주가	US$28.42
52주 최고치	US$35.38
52주 최저치	US$6.76
베타	0.82
11개월 변경	283.02%
3개월 변경 사항	233.57%
1년 변경 사항	133.53%
33년 변화	0.35%
5년 변화	217.54%
IPO 이후 변화	83.35%

최근 뉴스 및 업데이트

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Oct 07

Recent updates

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

주주 수익률

	SRRK	US Biotechs	US 마켓
7D	-6.6%	-0.7%	-1.6%
1Y	133.5%	19.8%	30.8%

수익률 대 산업: SRRK exceeded the US Biotechs industry which returned 20.1% over the past year.

수익률 대 시장: SRRK exceeded the US Market which returned 30.6% over the past year.

가격 변동성

Is SRRK's price volatile compared to industry and market?
SRRK volatility
SRRK Average Weekly Movement	101.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

안정적인 주가: SRRK's share price has been volatile over the past 3 months compared to the US market.

시간에 따른 변동성: SRRK's weekly volatility has increased from 52% to 102% over the past year.

회사 소개

설립	직원	CEO	웹사이트
2012	150	Jay Backstrom	scholarrock.com

바이오 제약 회사인 스콜라락 홀딩스는 단백질 성장 인자에 의한 신호 전달이 근본적인 역할을 하는 중증 질환 치료를 위한 의약품의 발견, 개발 및 공급에 주력하고 있습니다. 회사는 척수성 근위축증 치료를 위해 임상 3상 중인 미오스타틴 활성화 억제제 아피테그로맙과 항 PD-1 또는 항 PD-L1 항체 치료제와 같은 체크포인트 억제제 요법에 내성을 보이는 암 치료를 위해 임상 1상을 완료한 SRK-181을 개발하고 있습니다. 또한 신경 근육 장애, 심장 대사 장애, 암, 섬유증, 철분 제한성 빈혈 등 다양한 중증 질환을 치료할 수 있는 새로운 치료제를 제공하기 위해 제품 후보 파이프라인을 개발하고 있습니다.

Scholar Rock Holding Corporation 기본 사항 요약

Scholar Rock Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SRRK 기본 통계
시가총액	US$2.61b
수익(TTM)	-US$203.85m
수익(TTM)	n/a

0.0x

P/S 비율

-12.8x

P/E 비율

SRRK 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SRRK 손익 계산서(TTM)
수익	US$0
수익 비용	US$150.76m
총 이익	-US$150.76m
기타 비용	US$53.08m
수익	-US$203.85m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

Nov 12, 2024

주당 순이익(EPS)	-2.22
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	37.5%

SRRK 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SRRK 주식 개요

보상

위험 분석

Scholar Rock Holding Corporation 경쟁사

NasdaqGM:KROS

US$2.2b

NasdaqGM:INBX

US$1.8b

NasdaqGS:SNDX

US$1.6b

NasdaqGM:CRSP

US$4.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates